Profil
Jeffrey Greve is the founder of Delinia, Inc. (founded in 2015) and Kyverna Therapeutics, Inc. (founded in 2018).
At Delinia, he held the title of Chief Scientific Officer.
At Kyverna Therapeutics, he held the title of Chief Scientific Officer from 2018 to 2022.
Dr. Greve's former job was as Vice President-Research at aTyr Pharma, Inc. Dr. Greve earned a doctorate degree from the University of Washington and an undergraduate degree from The Johns Hopkins University.
Ehemalige bekannte Positionen von Jeffrey Greve
| Unternehmen | Position | Ende |
|---|---|---|
| KYVERNA THERAPEUTICS, INC. | Gründer | 23.08.2022 |
Delinea, Inc. (United States)
 Delinea, Inc. (United States) BiotechnologyHealth Technology Delinia, Inc. operates as a biotechnology company that develops novel therapeutics for the treatment of autoimmune diseases. Its main program is a molecule that potentiates and expands Regulatory T Cells, powerful immune cells that are critical to maintaining self-tolerance and immune system homeostasis. Tregs are critically important immune regulatory cells in the path physiology of cancer and autoimmune disease. Delinia was founded by Michael Rosenblum and Jeffrey Greve in 2015 and is headquartered in Summit, NJ. | Gründer | - |
| ATYR PHARMA, INC. | Technik-/Wissenschafts-/F&E-Leiter | - |
Ausbildung von Jeffrey Greve
| University of Washington | Doctorate Degree |
| The Johns Hopkins University | Undergraduate Degree |
Erfahrungen
Besetzte Positionen
Aktive
Inaktive
Börsennotierte Unternehmen
Private Unternehmen
Beziehungen
Beziehungen ersten Grades
Unternehmen ersten Grades
Herr
Frau
Aufsichtsräte
Führungskräfte
Unternehmensverbindungen
| Börsennotierte Unternehmen | 2 |
|---|---|
| ATYR PHARMA, INC. | Health Technology |
| KYVERNA THERAPEUTICS, INC. | Health Technology |
| Private Unternehmen | 1 |
|---|---|
Delinea, Inc. (United States)
Delinea, Inc. (United States) BiotechnologyHealth Technology Delinia, Inc. operates as a biotechnology company that develops novel therapeutics for the treatment of autoimmune diseases. Its main program is a molecule that potentiates and expands Regulatory T Cells, powerful immune cells that are critical to maintaining self-tolerance and immune system homeostasis. Tregs are critically important immune regulatory cells in the path physiology of cancer and autoimmune disease. Delinia was founded by Michael Rosenblum and Jeffrey Greve in 2015 and is headquartered in Summit, NJ. | Health Technology |
